Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Favipiravir versus Kaletra in hospitalized patients with COVID-19
IRCT20200318046812N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of favipiravir, lopinavir + ritonavir and hydroxychloroquine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Admission to intensive care unit, In-hospital mortality and 7 more. Started Apr 2020; status: completed.
02
Drugs
favipiravirlopinavir + ritonavirhydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200318046812N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200318046812N1.